05 Jan Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million
Posted at 01:00h
in Asia
Insilico Medicine, a Hong Kong-based AI-driven drug discovery company that intends to list in Hong Kong after it unveiled an initial public offering plan (IPO) last year, has sold its preclinical drug candidate for breast cancer treatment to Italy-based pharmaceutical company Menarini Group in...